HIGHLIGHTS Geological and geochemical sampling campaigns designed to guide effective targeting for drill programs in Q2 2025 ...

As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Eli Lilly & Co. will spend at least $27 billion to build four US manufacturing plants, the latest company to brace for the ...

Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains.

Medicare, the government-backed program for adults aged 65 and older and those with disabilities, only covers the use of ...

O presidente Luiz Inácio Lula da Silva demitiu nesta terça-feira a ministro da Saúde, Nísia Trindade, e a substituiu pelo ...

Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

The prevalence of type 2 diabetes is rising globally, with a disproportionate impact on individuals in low-income and middle-income countries, where access to care and new therapies is often limited.